Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bacteriophage Therapy for MSSA Prosthetic Joint Infection
NCT06456424Phase 2Active, not recruiting
- Sponsor
- University of Calgary
- Start
- Nov 2024
- Primary completion
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Single Strain Products, Multi-strain Products
- Countries
- 1
01
Overview
A Phase 2 trial of Zefylti, J1P3 in prosthetic joint infection (PJI), sponsored by University of Calgary. Started Nov 2024; status: active, not recruiting.
02
Drugs
ZefyltiJ1P3
03
Conditions
prosthetic joint infection (PJI)
Beyond the preview
Go deeper on NCT06456424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06456424.